INTRODUCTION: Prior research has shown that advanced stage nonsmall cell lung cancer (NSCLC) patients enrolled in hospice care receive less aggressive treatment at the end of life (EOL) without compromising survival. Our purpose was to profile the continuum of care of these patients, exploring the connection between hospice enrollment and quality indicators for excellence in EOL cancer care. METHODS: One hundred ninety-seven deceased stage IV NSCLC patients diagnosed between 2008 and 2010 at two separate tertiary care centers within the same county were identified. A retrospective review was conducted, collecting data from electronic medical records regarding antitumor treatment, postdiagnosis hospital visits and admissions, hospice referrals and enrollments, and circumstances surrounding the patient's death. Patients were grouped by their status of hospice enrollment, and the remainder of the measures compared accordingly. RESULTS: There was no significant difference found in total number of postdiagnosis hospital admissions between the patients who were enrolled in hospice and those who were not. However, the group who received hospice services had a significantly lower number of hospitalizations (p < 0.001), emergency department visits (p < 0.01), and intensive care unit admissions in the last 30 days of life (p < 0.001). The number of lines of chemotherapy received did not differ significantly between the groups. Median survival, measured by the length of time between diagnosis and death, was significantly longer for hospice patients (p = 0.02). CONCLUSIONS: This study demonstrates that, among patients with metastatic NSCLC, hospice enrollment was associated with optimized EOL oncological care and a significantly longer median survival.
INTRODUCTION: Prior research has shown that advanced stage nonsmall cell lung cancer (NSCLC) patients enrolled in hospice care receive less aggressive treatment at the end of life (EOL) without compromising survival. Our purpose was to profile the continuum of care of these patients, exploring the connection between hospice enrollment and quality indicators for excellence in EOL cancer care. METHODS: One hundred ninety-seven deceased stage IV NSCLCpatients diagnosed between 2008 and 2010 at two separate tertiary care centers within the same county were identified. A retrospective review was conducted, collecting data from electronic medical records regarding antitumor treatment, postdiagnosis hospital visits and admissions, hospice referrals and enrollments, and circumstances surrounding the patient's death. Patients were grouped by their status of hospice enrollment, and the remainder of the measures compared accordingly. RESULTS: There was no significant difference found in total number of postdiagnosis hospital admissions between the patients who were enrolled in hospice and those who were not. However, the group who received hospice services had a significantly lower number of hospitalizations (p < 0.001), emergency department visits (p < 0.01), and intensive care unit admissions in the last 30 days of life (p < 0.001). The number of lines of chemotherapy received did not differ significantly between the groups. Median survival, measured by the length of time between diagnosis and death, was significantly longer for hospice patients (p = 0.02). CONCLUSIONS: This study demonstrates that, among patients with metastatic NSCLC, hospice enrollment was associated with optimized EOL oncological care and a significantly longer median survival.
Authors: Craig C Earle; Bridget A Neville; Mary Beth Landrum; Jeffrey M Souza; Jane C Weeks; Susan D Block; Eva Grunfeld; John Z Ayanian Journal: Int J Qual Health Care Date: 2005-06-28 Impact factor: 2.038
Authors: Akiko M Saito; Mary Beth Landrum; Bridget A Neville; John Z Ayanian; Jane C Weeks; Craig C Earle Journal: J Palliat Med Date: 2011-07-18 Impact factor: 2.947
Authors: Joseph A Greer; William F Pirl; Vicki A Jackson; Alona Muzikansky; Inga T Lennes; Rebecca S Heist; Emily R Gallagher; Jennifer S Temel Journal: J Clin Oncol Date: 2011-12-27 Impact factor: 44.544
Authors: Jennifer S Temel; Joseph A Greer; Alona Muzikansky; Emily R Gallagher; Sonal Admane; Vicki A Jackson; Constance M Dahlin; Craig D Blinderman; Juliet Jacobsen; William F Pirl; J Andrew Billings; Thomas J Lynch Journal: N Engl J Med Date: 2010-08-19 Impact factor: 91.245
Authors: Jennifer S Temel; Jessica McCannon; Joseph A Greer; Vicki A Jackson; Patricia Ostler; William F Pirl; Thomas J Lynch; J Andrew Billings Journal: Cancer Date: 2008-08-15 Impact factor: 6.860
Authors: Haiden A Huskamp; Nancy L Keating; Jennifer L Malin; Alan M Zaslavsky; Jane C Weeks; Craig C Earle; Joan M Teno; Beth A Virnig; Katherine L Kahn; Yulei He; John Z Ayanian Journal: Arch Intern Med Date: 2009-05-25
Authors: Mali K Schneiter; Mohana B Karlekar; Marta A Crispens; Lauren S Prescott; Alaina J Brown Journal: Support Care Cancer Date: 2018-09-12 Impact factor: 3.603